Interleukin-33: a novel mediator with a role in distinct disease pathologies.
about
F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammationThe immune pathogenesis of scleroderma: context is everythingInterleukin-33 and Mast Cells Bridge Innate and Adaptive Immunity: From the Allergologist's PerspectiveRecombinant R-spondin2 and Wnt3a up- and down-regulate novel target genes in C57MG mouse mammary epithelial cellsIdentification and functional analysis of 9p24 amplified genes in human breast cancer.Association of interleukin-33 gene single nucleotide polymorphisms with ischemic stroke in north Chinese populationFocal adhesion kinase-mediated activation of glycogen synthase kinase 3β regulates IL-33 receptor internalization and IL-33 signaling.Th2 regulation of viral myocarditis in mice: different roles for TLR3 versus TRIF in progression to chronic disease.Microarray analysis reveals age-related differences in gene expression during the development of osteoarthritis in mice.Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients.Identification of candidate genes for histiocytoid cardiomyopathy (HC) using whole genome expression analysis: analyzing material from the HC registry.Geometrical Frustration in Interleukin-33 Decouples the Dynamics of the Functional Element from the Folding Transition State EnsembleMolecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge modelInterleukin-33 in the human placentaIL-33 promotes eosinophilia in vivo and antagonizes IL-5-dependent eosinophil hematopoiesis ex vivo.Anti-interleukin-33 Reduces Ovalbumin-Induced Nephrotoxicity and Expression of Kidney Injury Molecule-1.Association Between Vitamin D Deficiency and Allergic Diseases.The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovaniRole of the IL-33-ST2 axis in sepsis.Molecular basis of applied biological therapeutics.Pathophysiology of allergic inflammation.Immunopathogenesis of allergic disorders: current concepts.Plasma IL-33 in atopic patients correlates with pro-inflammatory cytokines and changes cholesterol transport protein expression: a surprising neutral overall impact on atherogenicity.Profibrotic interleukin-33 is correlated with uterine leiomyoma tumour burden.Association between IL-33 Gene Polymorphisms (rs1929992, rs7044343) and Systemic Lupus Erythematosus in a Chinese Han Population.The β-glucan receptor dectin-1 promotes lung immunopathology during fungal allergy via IL-22.An interleukin-33 gene polymorphism is a modifier for eosinophilia in rats.IL-33 promotes IL-10 production in macrophages: a role for IL-33 in macrophage foam cell formation.Alarmins in Frozen Shoulder: A Molecular Association Between Inflammation and Pain.Interleukin-33 promotes helper T cell type-2/17 inflammation in children with allergic rhinitis.Beneficial effect of anti-interleukin-33 on the murine model of allergic inflammation of the lower airway.Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis.IL-33/ST2 signalling and crosstalk with FcεRI and TLR4 is targeted by the parasitic worm product, ES-62.IL-33 neutralization suppresses lupus disease in lupus-prone mice.The role of IL-33 and its receptor ST2 in human nasal epithelium with allergic rhinitis.Ambiguous roles of innate lymphoid cells in chronic development of liver diseases.
P2860
Q24337221-8250A91C-28E6-40F8-BB74-CEB61636D798Q24633658-DB82FDE4-AC17-4D54-95A3-8DB687912E8AQ26775911-5EE9C3D6-50A2-4FCD-9037-9A298F615F23Q28478701-0B1BC7E9-3BAD-4D43-9D09-098ACA8FAD89Q34191958-E5CA1A76-D4D2-4A6A-AC1A-DBE74C4E3380Q35012550-E678D442-CD64-42C9-9D66-BEE2B7C71A58Q35189260-C24981D7-6F51-44F6-81CC-1F7AD53CA665Q35370925-2AB629E9-C3F4-4D4D-96E1-EFC15117CCF5Q35718244-42A85ADD-F57D-4D51-9CC0-54DF482C5202Q35785935-8574A69A-2146-444F-BEBE-7343ED6BB754Q35808338-AF208D7A-BF69-462A-9E45-45C77E7458E3Q35858724-E7B55317-A073-4B28-A80F-A5BE0A2CF96DQ35988587-0E3DCE63-EA56-4041-8FAC-0856B631716EQ36585708-CE042EC8-E38A-4283-9315-22D0DE6D3972Q36698549-772E0F43-33A0-46F8-B024-F858316275B6Q37064285-ACB6BFE2-0DB3-4A2B-B03D-4D60ADC96407Q37155258-E11AB565-6C17-414D-8131-D2240AC94F03Q37174541-3E0092D7-BE8D-42E4-BA7C-EE55C9EFBBF9Q37620811-09AE1D3D-66FD-48D8-9D2D-73610117822CQ37825467-D66BCBBC-7EB9-492C-BDAD-215F4FD44B3BQ37891126-21FD5A5F-4CB1-4B82-9327-22145252D827Q38085051-C7BE6CEA-3D87-4825-A982-6A971A5A0F2FQ38907279-8953DB2A-54C8-45BC-AA88-83E129BA1DCBQ39406925-6DFA1BB6-528E-4A78-BDE6-FDCD64BD4EA5Q40591524-7B8152F1-95C2-49CE-8A81-207FF15247E4Q41812432-C9871877-9A27-4950-BB33-4DE8B0B4B019Q45798397-2E5FDE9F-EE3F-4EF0-9133-55AF7BCC24A3Q47109097-502A404D-05D9-4C83-9F57-E2B967845580Q47347447-1DF56D56-96E7-4C59-8F1A-903AF7B91913Q47389893-E20AB620-FE33-45D2-AC02-23D84D30BE27Q53368128-41E69B52-1ED8-477D-B4EA-C6E5AE08C1CCQ53399787-08180A77-DD98-4181-9859-0B9B46A808CBQ54255800-F4A3F20C-E8B2-4A0C-8E23-49D0BA653AA0Q54323094-FCDA93CE-4D39-4F23-B9AA-5C65FBF21BF9Q54330061-644C40E0-6622-4FE1-A23F-957EADF262CAQ55208795-F36F282C-EB2C-43E5-86DC-47DADA405050
P2860
Interleukin-33: a novel mediator with a role in distinct disease pathologies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interleukin-33: a novel mediator with a role in distinct disease pathologies.
@en
Interleukin-33: a novel mediator with a role in distinct disease pathologies.
@nl
type
label
Interleukin-33: a novel mediator with a role in distinct disease pathologies.
@en
Interleukin-33: a novel mediator with a role in distinct disease pathologies.
@nl
prefLabel
Interleukin-33: a novel mediator with a role in distinct disease pathologies.
@en
Interleukin-33: a novel mediator with a role in distinct disease pathologies.
@nl
P2860
P1476
Interleukin-33: a novel mediator with a role in distinct disease pathologies
@en
P2093
B Stolarski
M Kurowska-Stolarska
P2860
P356
10.1111/J.1365-2796.2010.02316.X
P407
P577
2011-01-01T00:00:00Z